Member Info for checkricky

Confused Shorts are running for the laxatives, must of had a whiff of some leaked news due to come out, LLLOOOLLL

Good to see HEMO attempt a breakout, when this share is really ready you will all see a true TAKE OFF :)

Goood Moooorning Investors HEMO getting ready to rocket this will make higher highs and is way way over sold

When we get any form of RNS this will fly big time

Someone has a sore JackHole
Warning On The Knob Says: DO TRY TO DISTURB THE HEMO RECOVERY

If you are nervous or mentally disturbed don't come to the hemo bb and go on about how bad things are, if you are de raping the share and looking for a cheap bargain entry price then your late to the party, come back in a few months time and then see what your money can buy you, by that time the share price will be a lot higher than the price now...

Need a few days rest from pure negativity every other day a new pest pops up a (HEMO HERO) as if they know more about the company then anyone else with a hidden negative agenda.

And for the record I am invested and I am VERY HAPPY TO HOLD and most invested here know why. This share is 2p very very low entry price but when the churning comes to an end in a few days time the share will start to take off upwards simple.

Time for me to STAY FOUCUSED AND STAY POSITIVE in a few days the churning will be all over and the good days can start...
Anyway time for get my gym workout now, before the peak time know it all hero's arrive. Have a good day investors...

Investors hope your all having a Good Monday Morning looks like HEMO should have a buzzy week this week. I'm looking for some positives moves to the upside this week as well as the usual MM tricks along the way.

Monday Morning presidential dump should be over now and with a few early profit takers out the way we should hopefully get ready for a strong move to the upside share price has lots and lots of ground to make up yet imo the share price is very low for what HEMO has in the pipeline.

Looks like some of the fat churning may also be done now only bits and drabs left.

Thanks you for taking your personal time out time out and putting together your assessment on HEMO

With so many investors that know a lot about so many companies, you will only have a handful that will take out the time to put the researched work out for others to look at. Once again thank you and anyone who has invested or thinking of investing in HEMO it's well worth a read

https://docs.google.com/document/d/1IjlyCSjI9_vjc_KJA8WCGR2n5g5-mTCOXsTu1ZDbSwo/edit

Good Morning investors another cracking sunny day with a Blue sky's and a fresh breeze absolutely spot on day.

Everyone has had a good few days to buy under 2p now during the churning and a few opportunists have taken advantage of the very low price of HEMO, who are setting the road map to do some amazing things to save lives. OK we are going to get a few flip flopping day as this share price gets ready for take off. So fasten your seat belts and enjoy the ride and the UK weather. Watch this space for when the RNS lands no one will be able to buy this share for peanuts share price will be nowhere near 2p.

As always keep up the good work, stay positive and do your homework

How does that Tread Title look for the Saint's lol ...

And soon the DE Rampers will be gone into the sunset only to destroy another company

Well HEMO is fighting back strong now

And lets not forget this has been way over sold by - 80% in the last 6 months so a big bounce is due just from a technical and new fundamentals point of view

I would not say no to a rise to close the 5p to 7p gap that so many are on about, Who knows we may soon be testing them levels

Look we have a few negative posters that keep popping up going on about the same thing and I think many are sick of it. That HEMO cannot go up on NO NEWS.

Well it can and it's for the opposite reasons of why this share fell in the first place simple and taking the dilution into account we should see the share price rise without news

So the way I look at it is and I am sure many INVESTED in HEMO think the same we all know why the share price fell from 15p or 10p what ever!! so it's all about the way the company was being mugged by the Mint funding relationship OK !!!
Right well it was needed at that moment in time and we all know it was a bad relationship simple..... So for the record I am not talking about a rise to 15p or anything as you will need news for that and I am sure we will be getting some and more in the coming weeks and months anyway

Reasons for the share price to rise WITH OUT NEWS AND JUST COMMEN SENCE INVESTING
. NOW THE MINT FACILITY HAS BEEN TERMINATED. BIG BOOST
. NOW HEMO HAS £10 MILLION IN THE BANK & MARKET CAP OF £21MILLION. BIG BOOST
. BOD BUYING SHOWS CONFIDENCE. BIG BOOST
. 433,333,333 SHARES MOSTLY OUT THE WAY. MASSIVE BIG BOOST
. NO OTHER CONVERTIBLE LOAN NOTES OR CONVERSION NOTICES REMAIN OUTSTANDING. BIG BOOST
. U.S. APPROVAL & ISSUANCE OF CDX ANTIBODY PATENT. BIG BOOST
. WORLD WIDE PATENTS PENDING. WILL ALSO BE A BIG BOOST
. PRODUCT MOVING TOWARDS CLINICAL TRIALS and updates will be provided to shareholders in due time. The Directors are pleased to note the continued faith in the Company shown by shareholders.

Also I think we should be pleasantly surprised by the time we get to the AGM meeting held on 25 June 2021 so hold on to your hard earned shares for some real upside. And don't let De Rampers and Bed Wetter's fool you into selling at such a low low price.

It's a great bluesky day
Sun is out just the ticket, so I'm off for a bike ride

Now that HEMO is off the lows which was way oversold, I think I should be able to enjoy other things in life and let the company get on with the real magical work rather than sit on a bb nit picking at post all day that's to sad of a life for me.

Hope you all have a great day investors....

No particular reason. And it's more in line with what I am doing and my strategy as it says on the Tin or the Title, I would not sell any HEMO shares now I am only Buying. No ramp intended but you have to look at how oversold this share is and I would go as far as to say I think most investors are buying and doing the same. And if you have time on your hands you may want to go back and take a look you maybe surprised to find other titles have been used in the past....

And just to conclude I am a large holder not just a dreamer sitting on the side lines, for two reasons one is I am invested in this company so that it goes on and saves life and does well and secondly I can make a return on my investment and looking at the fundamentals and technical developments in the pipeline I think I am making the right moves. Everyone has the opportunity to do the same or whatever floats there boat ....

Market Capitalisation £20m now, much better days are coming for this company just wait for the share price start to rise in big numbers and then watch the attention HEMO will get.

B1ll stop trying to get my attention
When you starting going on about your so called bet the share price was 1.78p last week as I said I am not a gambler I am a investor.

Out of sympathy I stated I will take your bet on at 1.80p as the price had moved up in a matter of mins that's what I agreed to
you said 1.90p THAT@S YOUR PRICE IT'S NOT WHAT I SAID OR AGREED TO that's your bet also along with trying to silent a few other posters (no names ). Go back and have a look at my message if you have a lot of free time on your hands...

You now need to Take your 10 days off now along with 3 DERAMPERS!! pick who ever you want it's still going to be one person with different 3 Id's as that's how they work...

Getting Better by the day now as the MM running out of tricks now, I better get my dancing shoes on for the real rally soon.

Really Starting to Fly now was well overdue!!!

Back two 2p two buy. Good to see the direction is up. Good to also see strong buying this morning. Tick up just now so happy for this to continue and we all know when we get any news this will rise strong....

Staying positive for a strong close anything above 2p will do at this stage just to give direction

About AML

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

Further information about the development of the Company’s bi-specific antibody technology can be found on Hemogenyx Pharmaceuticals’ web site: https://hemogenyx.com/technology/cdx-antibodies.

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

If fully and successfully developed, the Method would obviate the need for highly toxic conditioning protocols, including chemotherapy, in patients who require BM/HSC transplantation, and would result in the development of a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor.

The bi-specific antibody described in the issued patent was developed by the Company and the patent application for it first filed in 2016. That filing, together with data showing its efficacy in humanised mice with respect to BM/HSC transplantation conditioning, formed the basis of the Company’s collaboration with a leading global pharmaceutical company (“GlobalCo”) to develop CDX further (https://hemogenyx.com/investors/announcements/announcement/2018/
Hemogenyx-Pharma-Plc—Development-Agreement/).

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: “The issue of this patent is significant for the Company because it protects the Company’s IP in one of its lead product candidates, while further solidifying its leading position in the field of the development of ground breaking therapies for the treatment of blood cancers and BM/HSC transplantation conditioning. The Company continues to progress the laboratory and commercial development of the CDX antibody, and is focused on bringing it to clinical trials.”

Just to keep the new blood up to speed taken from ST

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.

Entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office. The patent was issued as Patent Number US 11,021,536 B2 (https://tinyurl.com/yspjv89w).

This patent covers a method of use of a bi-specific antibody (“CDX”), one of the Company’s original and lead product candidates, for conditioning bone marrow/hematopoietic stem cell (“BM/HSC”) transplantation. It also covers a composition of matter (a subset of sequences) of monoclonal antibodies against target proteins existing on the surface of hematopoietic stem cells/hematopoietic progenitors (“HSC/HP”), and/or a number of leukemias such as acute myeloid leukemia (“AML”) as well as a protein that exists on the surface of immune cells (T cells).

The method described in the patent (the “Method”) was invented by Dr Vladislav Sandler, CEO and Co-founder of Hemogenyx Pharmaceuticals, working alone, and was then further developed and refined together with the Company’s team of scientists in its laboratory facilities in New York City. The patent provides a method for preparing or conditioning of BM/HSC transplantation in lieu of the traditional conditioning protocol involving chemotherapy, which is highly toxic. The Method provides a recombinant single chain bi-specific antibody that binds to both human FMS-like tyrosine kinase 3 (FLT3) on the surface of “unwanted cells” and human CD3 on the surface of T cells, and the administering of a therapeutic amount of a pharmaceutical composition comprising the bi-specific antibody to the patient.